Hepatitis C virus therapeutics: Editing enzymes promising therapeutic targets?

Hepatology

Volumn 54, Issue 2, 2011, Pages 742-742

  Alisi, Anna ^a   Tomaselli, Sara ^a   Balsano, Clara ^b   Gallo, Angela ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE ACTING ON RNA; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; MESSENGER RNA; UNCLASSIFIED DRUG;

DRUG TARGETING; GENE SILENCING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LETTER; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REPLICON; UPREGULATION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADENOSINE DEAMINASE; CYTIDINE DEAMINASE; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 79960741433     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24409     Document Type: Letter

References (4)

1. Peng ZG, Zhao ZY, Li YP, Wang YP, Hao LH, Fan B, et al. Host apolipoprotein b messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology 2011; 53: 1080-1089.
2. Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 2010; 12: e4.
3. Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011; 411: 180-193.
4. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol 2005; 79: 6291-6298.